Enciso Nathaly, Amiel José, Pando John, Enciso Javier
Laboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Perú.
Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain.
Vet World. 2019 Nov;12(11):1747-1754. doi: 10.14202/vetworld.2019.1747-1754. Epub 2019 Nov 8.
The aim of this pilot study was to evaluate the therapeutic and safety performance of an intramuscular treatment protocol of multidose of allogeneic adipose stem cells (ASCs) isolated, characterized, and expanded from a healthy canine donor.
Twelve dogs diagnosed with canine atopic dermatitis (CAD) were intramuscularly treated with 0.5×10 of cryopreserved ASCs from a healthy immunized young canine free donor weekly for 6 weeks. Treatment efficacy was evaluated by the pruritus index and the CAD Lesion Index (CADLI) test. Safety and adverse effects were determined by injection site reaction, weight, blood chemistry, liver function, and whole blood count.
Canine ASCs obtained from a donor met the minimum qualities required for this type of cells and showed viability of 90% after thawing. The efficacy of the CADLI score and the pruritus index in 12 dogs with atopic dermatitis was statistically significant efficacy. No adverse reactions were observed at the intramuscular application site, or in relation to animal weight, blood cell populations, or liver and renal function.
These results suggest that intramuscular administration of cryopreserved ASCs to dogs with atopic dermatitis is a promising cellular therapeutic product for the relief of the symptoms of this disease; however, the duration of the effects obtained with this dose and with other doses should be evaluated, as well as possible immune reactions. As far as we know, this is the first report of the use of multiple intramuscular doses cryopreserved ASCs to treat atopic dermatitis.
本初步研究的目的是评估从健康犬类供体分离、鉴定和扩增的多剂量同种异体脂肪干细胞（ASC）肌肉注射治疗方案的治疗效果和安全性。
12只被诊断为犬特应性皮炎（CAD）的犬，每周肌肉注射0.5×10⁶个来自健康免疫年轻犬类免费供体的冷冻保存的ASC，共治疗6周。通过瘙痒指数和CAD病变指数（CADLI）测试评估治疗效果。通过注射部位反应、体重、血液化学、肝功能和全血细胞计数确定安全性和不良反应。
从供体获得的犬ASC符合此类细胞所需的最低质量标准，解冻后存活率达90%。12只特应性皮炎犬的CADLI评分和瘙痒指数的疗效具有统计学意义。在肌肉注射部位未观察到不良反应，在动物体重、血细胞群体或肝肾功能方面也未观察到不良反应。
这些结果表明，对特应性皮炎犬肌肉注射冷冻保存的ASC是一种有望缓解该病症状的细胞治疗产品；然而，应评估此剂量和其他剂量所获得效果的持续时间以及可能的免疫反应。据我们所知，这是首次报道使用多剂量肌肉注射冷冻保存的ASC治疗特应性皮炎。
